Med. praxi. 2012;9(11):432-434

Age-related macular degeneration - epidemiology, risk factors, diagnosis and therapy

MUDr.Petr Kolář, Ph.D.
Oční klinika Lékařské fakulty Masarykovy univerzity a Fakultní nemocnice Brno

Age-related macular degeneration (AMD) is the world‘s one of the main causes of practical blindness. The disease mainly affects patients

older than 60 years and its prevalence increases with aging. In developed countries, the any form of AMD affects up to 20 % of the population.

Advanced forms of the disease lead to practical blindness. The main symptoms are distorted vision, scotomas in the visual field

and decrease of visual acuity. The main risk factors for the disease are cigarette smoking, inadequate intake of antioxidants, hypertension,

genetic factors, excessive exposure to sunlight. For diagnosis of disease is required ophthalmic examination including fluorescein

angiography (FA) and optical coherence tomography (OCT). Supplementation with antioxidants slows disease progression. Treatment

of the disease includes the administration of anti-VEGF agents in the vitreous.

Keywords: age-related macular degeneration, cigarette smoking, genetic factors, antioxidants, anti-VEGF therapy

Published: December 1, 2012  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kolář P. Age-related macular degeneration - epidemiology, risk factors, diagnosis and therapy. Med. praxi. 2012;9(11):432-434.
Download citation

References

  1. Bloch SB, Larsen M, Munch IC. Incidence of legal blindness from age-related macular degeneration in Denmark: year 2000 to 2010. Am J Ophthalmol 2012; 153: 209-213. Go to original source... Go to PubMed...
  2. Klein R, Klein BE, Knudtson MD, Meuer SM, Swift M, Gangnon RE. Fifteen-year cumulative incidence of age-related macular degeneration: the Beaver Dam Eye Study. Ophthalmology 2007; 114: 253-262. Go to original source... Go to PubMed...
  3. Laude A, Cackett PD, Vithana EN, et al. Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retin Eye Res 2010; 29: 19-29. Go to original source... Go to PubMed...
  4. Chakravarthy U, Wong TY, Fletcher A, et al. Clinical risk factors for age-related macular degeneration: a systematic review and meta-analysis. BMC Ophthalmol 2010; 10: 31. Go to original source... Go to PubMed...
  5. Kolář P. a kol. Věkem podmíněná makulární degenerace. Praha: Grada 2008.
  6. Wong TY, Chakravarthy U, Klein R, et al. The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008; 115: 116-126. Go to original source... Go to PubMed...
  7. Lamoureux EL, Mitchell P, Rees G, et al. Impact of early and late age-related macular degeneration on vision-specific functioning. Br J Ophthalmol 2011; 95: 666-670. Go to original source... Go to PubMed...
  8. Lim L, Mitchell P, Seddon JM, Holz FG, Wong TY. Ophthalmology 1: Age-related Macular Degeneration. Lancet 2012; 379: 1728-1738. Go to original source... Go to PubMed...
  9. Papadopoulos N, Martin J, Ruan Q, et al. Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 2012; 15(2): 171-185. Go to original source... Go to PubMed...
  10. Guidelines for using verteporfin (Visudyne) in photodynamic therapy to treat choroidal neovascularization due to age-related macular degeneration and other causes. Retina 2002; 22: 6-18.
  11. Macular Photocoagulation Study Group. Argon laser photocoagulation for neovascular maculopathy. Three-year results from randomized clinical trials. Arch Ophthalmol 1986; 104: 694-701. Go to original source... Go to PubMed...
  12. Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch Ophthalmol 1982; 100: 912-918. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.